These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27799398)

  • 1. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns.
    Kawano-Dourado L; Zampieri F; Cavalcanti AB; Damiani LP; Kairalla RA
    Eur Respir J; 2016 Nov; 48(5):1523-1524. PubMed ID: 27799398
    [No Abstract]   [Full Text] [Related]  

  • 2. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns.
    Kreuter M; Wijsenbeek MS; Vasakova M; Spagnolo P; Kolb M; Costabel U; Weycker D; Kirchgaessler KU; Maher TM
    Eur Respir J; 2016 Nov; 48(5):1524-1526. PubMed ID: 27799399
    [No Abstract]   [Full Text] [Related]  

  • 3. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.
    Kreuter M; Wijsenbeek MS; Vasakova M; Spagnolo P; Kolb M; Costabel U; Weycker D; Kirchgaessler KU; Maher TM
    Eur Respir J; 2016 Jun; 47(6):1776-84. PubMed ID: 27103382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?
    Janssen R
    Am J Respir Crit Care Med; 2017 Jan; 195(2):269-270. PubMed ID: 28084819
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply: Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?
    Raghu G; Rochwerg B
    Am J Respir Crit Care Med; 2017 Jan; 195(2):271. PubMed ID: 28084827
    [No Abstract]   [Full Text] [Related]  

  • 6. "Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis." Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. Eur Respir J 2016; 47: 1776-1784.
    Eur Respir J; 2016 Aug; 48(2):593. PubMed ID: 27478193
    [No Abstract]   [Full Text] [Related]  

  • 7. ERJ June Podcast: unfavourable effects of oral anticoagulants on survival in idiopathic pulmonary fibrosis.
    Eur Respir J; 2016 Jun; 47(6):E66. PubMed ID: 27246087
    [No Abstract]   [Full Text] [Related]  

  • 8. Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin?
    Tzouvelekis A; Margaritopoulos G; Loukides S; Bouros D
    Am J Respir Crit Care Med; 2013 Jan; 187(2):213-4. PubMed ID: 23322796
    [No Abstract]   [Full Text] [Related]  

  • 9. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup?
    Kubo H; Yanai M; Azuma A
    Am J Respir Crit Care Med; 2013 May; 187(9):1029-30. PubMed ID: 23634865
    [No Abstract]   [Full Text] [Related]  

  • 10. Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis.
    Kolb M; Jenkins G; Richeldi L
    Thorax; 2016 May; 71(5):399-400. PubMed ID: 27068097
    [No Abstract]   [Full Text] [Related]  

  • 11. Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis.
    Kobayashi T; Hataji O; Fujimoto H; D'Alessandro-Gabazza C; Yasuma T; Gabazza EC
    Am J Respir Crit Care Med; 2020 Jun; 201(11):1449-1450. PubMed ID: 32150439
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence-based recommendations in idiopathic pulmonary fibrosis: a year is a long time in interstitial lung disease.
    Müller-Quernheim J; Wells A
    Am J Respir Crit Care Med; 2012 Jul; 186(1):5-7. PubMed ID: 22753682
    [No Abstract]   [Full Text] [Related]  

  • 13. [Idiopathic pulmonary fibrosis or atypical tuberculosis].
    PANA C; SPINA G; PERELLI A
    Ann Ist Carlo Forlanini; 1955; 15(3):247-65. PubMed ID: 13302974
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial.
    Kondoh Y; Azuma A; Tagawa J; Homma S
    Am J Respir Crit Care Med; 2020 Jul; 202(1):151-152. PubMed ID: 32228231
    [No Abstract]   [Full Text] [Related]  

  • 15. Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial.
    Horita N; Takeshi K
    Am J Respir Crit Care Med; 2020 Jul; 202(1):150-151. PubMed ID: 32228230
    [No Abstract]   [Full Text] [Related]  

  • 16. [Considerations on the radiological aspects of idiopathic pulmonary fibrosis & of tuberculous fibrotic manifestations].
    MARTINOTTI G; MOTTA R
    Minerva Med; 1959 May; 50(39):1517-27. PubMed ID: 13666583
    [No Abstract]   [Full Text] [Related]  

  • 17. Secondary spontaneous pneumothorax in idiopathic pulmonary fibrosis: Grim news.
    Porcel JM
    Respirology; 2018 May; 23(5):448-449. PubMed ID: 29316046
    [No Abstract]   [Full Text] [Related]  

  • 18. Idiopathic pulmonary fibrosis; roentgenologic findings.
    ROBBINS LL
    Radiology; 1948 Oct; 51(4):459-67. PubMed ID: 18893278
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnosing idiopathic pulmonary fibrosis without a lung biopsy: honeycombing not required.
    Homer R; Lederer DJ
    Thorax; 2017 May; 72(5):391-392. PubMed ID: 28280234
    [No Abstract]   [Full Text] [Related]  

  • 20. Guidelines for Idiopathic Pulmonary Fibrosis: Everything Flows.
    Tzilas V; Bouros E; Tzouvelekis A; Bouros D
    Respiration; 2017; 93(6):401-403. PubMed ID: 28445891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.